

DESCRIPTION


Species Reactivity	Equine
Specificity	Detects equine IL-1 β /IL-1F2 in direct ELISAs and Western blots. In direct ELISAs, approximately 100% cross-reactivity with recombinant canine IL-1 β , recombinant feline IL-1 β , and recombinant human IL-1 β is observed, 40% cross-reactivity with recombinant porcine IL-1 β , recombinant mouse IL-1 β , and recombinant rat IL-1 β is observed, and 10% cross-reactivity with recombinant cotton rat IL-1 β and is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant equine IL-1 β /IL-1F2 Ala116-Ala268 (Glu179Gly, Met188Thr, Thr194Ile, Ser245Lys, Arg256Gln) Accession # Q28386
Endotoxin Level	<0.10 EU per 1 μ g of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 μ m filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μ g/mL	Recombinant Equine IL-1 β /IL-1F2 (Catalog # 3340-EL)
Immunocytochemistry	5-15 μ g/mL	Immersion fixed equine peripheral blood mononuclear cells
Neutralization		Measured by its ability to neutralize IL-1 β /IL-1F2-induced proliferation in the D10.G4.1 mouse helper T cell line. Symons, J. A. <i>et al.</i> (1987) in <i>Lymphokines and Interferons, a Practical Approach</i> . Clemens, M. J. <i>et al.</i> (eds): IRL Press. 272. The Neutralization Dose (ND ₅₀) is typically 0.05-0.25 μ g/mL in the presence of 100 pg/mL Recombinant Equine IL-1 β /IL-1F2 and 1.25 μ g/mL concanavalin A.

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

IL-1 is a name that designates two pleiotropic cytokines, IL-1 α (IL-1F1) and IL-1 β (IL-1F2), which are the products of distinct genes. IL-1 α and IL-1 β are structurally related polypeptides that share approximately 27% amino acid (aa) identity in equine. Both proteins are produced by a wide variety of cells in response to inflammatory agents, infections, or microbial endotoxins. While IL-1 α and IL-1 β are regulated independently, they bind to the same receptor and exert identical biological effects. IL-1 RI binds directly to IL-1 α or IL-1 β and then associates with IL-1 R accessory protein (IL-1 R3/IL-1 R AcP) to form a high-affinity receptor complex that is competent for signal transduction. IL-1 RII has high affinity for IL-1 β but functions as a decoy receptor and negative regulator of IL-1 β activity. IL-1ra functions as a competitive antagonist by preventing IL-1 α and IL-1 β from interacting with IL-1 RI (1-4). The equine IL-1 β cDNA encodes a 268 aa precursor. A 115 aa propeptide is cleaved intracellularly by the cysteine protease IL-1 β -converting enzyme (Caspase-1/ICE) to generate the active cytokine (5-7). An alternatively spliced form of equine IL-1 β has a deletion which encompasses the Caspase-1 cleavage site and potentially results in a membrane-associated form (8). The 17 kDa mature equine IL-1 β shares 65%-75% aa sequence identity with canine, cotton rat, feline, human, mouse, porcine, rat, and rhesus IL-1 β .

References:

1. Allan, S.M. *et al.* (2005) *Nat. Rev. Immunol.* **5**:629.
2. Boraschi, D. and A. Tagliabue (2006) *Vitam. Horm.* **74**:229.
3. Kornman, K.S. (2006) *Am. J. Clin. Nutr.* **83**:475S.
4. Isoda, K. and F. Ohsuzu (2006) *J. Atheroscler. Thromb.* **13**:21.
5. Kato, H. *et al.* (1997) *Vet. Immunol. Immunopathol.* **48**:221.
6. Howard, R.D. *et al.* (1998) *Am. J. Vet. Res.* **59**:704.
7. Martinon, F. and J. Tschopp (2007) *Cell Death Differ.* **14**:10.
8. Kato, H. *et al.* (1996) *Gene* **177**:11.